Evidence map›Paper›PMID 31898874›Full record

ArticleObesity (Silver Spring, Md.)2020

History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial.

Look AHEAD Research Group, Cora E Lewis, John P Bantle, Alain G Bertoni, George Blackburn, Frederick L Brancati, George A Bray, Lawrence J Cheskin, Jeffrey M Curtis, Caitlin Egan and 34 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity (Silver Spring, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.Diabetic medicine : a journal of the British Diabetic Association · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Look AHEAD Research Group
Cora E LewisUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-2301-5796
John P BantleUniversity of Minnesota, Minneapolis, Minnesota, USA.
Alain G BertoniWake Forest University, Winston-Salem, North Carolina, USA.
George BlackburnBeth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Frederick L BrancatiJohns Hopkins University, Baltimore, Maryland, USA.
George A BrayPennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Lawrence J CheskinJohns Hopkins University, Baltimore, Maryland, USA.
Jeffrey M CurtisSouthwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases and St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Caitlin EganThe Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.
Mary EvansNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
John P ForeytBaylor College of Medicine, Houston, Texas, USA.
Siran GhazarianUniversity of Southern California, Los Angeles, California, USA.
Bethany Barone GibbsUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Stephen P GlasserUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Edward W GreggCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Helen P HazudaUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Louise HessonUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
James O HillUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Edward S HortonJoslin Diabetes Center, Boston, Massachusetts, USA.
Van S HubbardNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
John M JakicicUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6800-9368
Robert W JefferyUniversity of Minnesota, Minneapolis, Minnesota, USA.
Karen C JohnsonThe University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0002-3493-4077
Steven E KahnUS Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.
Abbas E KitabchiThe University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Dalane KitzmanWake Forest University, Winston-Salem, North Carolina, USA.
William C KnowlerSouthwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
Edward LipkinUS Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.
Sara MichaelsSouthwestern American Indian Center, Shiprock, New Mexico, USA.
Maria G MontezUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
David M NathanMassachusetts General Hospital, Boston, Massachusetts, USA.
Ebenezer NyenweThe University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Jennifer PatricioSt. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.
Anne PetersUniversity of Southern California, Los Angeles, California, USA.
Xavier Pi-SunyerSt. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.
Henry PownallBaylor College of Medicine, Houston, Texas, USA.
David M ReboussinWake Forest University, Winston-Salem, North Carolina, USA.
Donna H RyanPennington Biomedical Research Center, Baton Rouge, Louisiana, USA.ORCID 0000-0002-7862-2526
Thomas A WaddenUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-0438-4609
Lynne E WagenknechtWake Forest University, Winston-Salem, North Carolina, USA.
Holly WyattUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rena R WingThe Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.ORCID 0000-0002-0918-8252
Susan Z YanovskiNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZAIA, JOHN A · 1985 to 2010
$76.4M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
Look AHEAD: Action for Health in DiabetesU01DK057136 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 1999 to 2020
$54.9M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KOSMISKI, LISA A. · 1985 to 2008
$52.6M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, EMERY N · 1985 to 2008
$37.4M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Wendy M Kohrt · 1995 to 2026
$32.6M
Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI James O Hill · 2000 to 2026
$31.9M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER S BRACH · 2004 to 2026
$28.6M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FERRER, ROBERT L · 1985 to 2008
$23.1M
CDC HHSNCRR NIH HHS M01 RR000043NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01 RR000211NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01 RR002719NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR025758NIA NIH HHS P30 AG024827NIA NIH HHS U01 AG073697NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079626NIDDK NIH HHS P30 DK079637NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219NINR NIH HHS
6 · The paper itself

Abstract

objectiveTo examine the effects of an intensive lifestyle intervention (ILI) on cardiovascular disease (CVD), the Action for Health in Diabetes (Look AHEAD) trial randomized 5,145 participants with type 2 diabetes and overweight/obesity to a ILI or diabetes support and education. Although the primary outcome did not differ between the groups, there was suggestive evidence of heterogeneity for prespecified baseline CVD history subgroups (interaction P = 0.063). Event rates were higher in the ILI group among those with a CVD history (hazard ratio 1.13 [95% CI: 0.90-1.41]) and lower among those without CVD (hazard ratio 0.86 [95% CI: 0.72-1.02]).

methodsThis study conducted post hoc analyses of the rates of the primary composite outcome and components, adjudicated cardiovascular death, nonfatal myocardial infarction (MI), stroke, and hospitalization for angina, as well as three secondary composite cardiovascular outcomes.

resultsInteraction P values for the primary and two secondary composites were similar (0.060-0.064). Of components, the interaction was significant for nonfatal MI (P = 0.035). This interaction was not due to confounding by baseline variables, different intervention responses for weight loss and physical fitness, or hypoglycemic events. In those with a CVD history, statin use was high and similar by group. In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group.

conclusionsIntervention response heterogeneity was significant for nonfatal MI. Response heterogeneity may need consideration in a CVD-outcome trial design.

Indexed as

Life StyleCardiovascular DiseasesFemaleHumansMaleMiddle Aged

Identifiers

PMID31898874
PMCPMC6980987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.